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Abstract
Background: Berberine (BBR) is a drug with multiple effects on cellular energy metabolism. The present study
explored answers to the question of which CYP450 (Cytochrome P450) isoenzymes execute the phase-I
transformation for BBR, and what are the bioactivities of its metabolites on energy pathways.
Methods: BBR metabolites were detected using LC-MS/MS. Computer-assistant docking technology as well as
bioassays with recombinant CYP450s were employed to identify CYP450 isoenzymes responsible for BBR phase-I
transformation. Bioactivities of BBR metabolites in liver cells were examined with real time RT-PCR and kinase
phosphorylation assay.
Results: In rat experiments, 4 major metabolites of BBR, berberrubine (M1), thalifendine (M2),
demethyleneberberine (M3) and jatrorrhizine (M4) were identified in rat’s livers using LC-MS/MS (liquid
chromatography-tandem mass spectrometry). In the cell-free transformation reactions, M2 and M3 were detectable
after incubating BBR with rCYP450s or human liver microsomes; however, M1 and M4 were below detective level.
CYP2D6 and CYP1A2 played a major role in transforming BBR into M2; CYP2D6, CYP1A2 and CYP3A4 were for M3
production. The hepatocyte culture showed that BBR was active in enhancing the expression of insulin receptor
(InsR) and low-density-lipoprotein receptor (LDLR) mRNA, as well as in activating AMP-activated protein kinase
(AMPK). BBR’s metabolites, M1-M4, remained to be active in up-regulating InsR expression with a potency reduced
by 50-70%; LDLR mRNA was increased only by M1 or M2 (but not M3 and M4) with an activity level 35% or 26%
of that of BBR, respectively. Similarly, AMPK-a phosphorylation was enhanced by M1 and M2 only, with a degree
less than that of BBR.
Conclusions: Four major BBR metabolites (M1-M4) were identified after phase-I transformation in rat liver. Cell-free
reactions showed that CYP2D6, CYP1A2 and CYP3A4 seemed to be the dominant CYP450 isoenzymes transforming
BBR into its metabolites M2 and M3. BBR’s metabolites remained to be active on BBR’s targets (InsR, LDLR, and
AMPK) but with reduced potency.
Background
Berberine (BBR, Figure 1) is a natural compound iso-
lated from Coptis chinensis and is for decades an over-
the-count medicine in China for diarrhea [1]. Recently,
accumulated research has identified BBR to be an effec-
tive drug in treating hyperlipidemia as well as hypergly-
cemia [2-4]. Clinical studies showed that oral
administration of BBR caused significant reduction of
blood cholesterol, triglyceride as well as glucose in
patients with hyperlipidemia and type 2 diabetes
[2,3,5-7], with no side-effects on liver, kidney and mus-
cle [2,5]. Mechanism studies have identified several
important modes of action involved in the activities of
BBR. The cholesterol-lowering effect was associated
with extracellular-signal-regulated kinase (ERK)
mediated LDLR mRNA up-regulation [2,8]; the glucose-
lowering effect mainly resulted from the protein kinase
C (PKC) mediated InsR expression and the activation of
AMPK [3,4,9,10]. The observed reduction of triglyceride
by BBR might reflect its synergistic effect on both sugar
and lipid metabolism [2-4].
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fied in human blood after Phase I metabolism [11]; how-
ever, human CYP450 isoenzymes that are responsible
for BBR phase-I transformation remain to be identified.
Furthermore, bioactivities of the metabolites on the
pathways mentioned above are also unknown. As most
of our previous experiments for BBR were done in
CYP450 positive human hepatocytes, HepG2 and Bel-
7402 [2-4], we were curious to learn which of the
CYP450 isoenzymes are involved in BBR phase-I meta-
bolism, and what are the bioactivities of the BBR
metabolites. Answers to these questions might be
important for patient selection in BBR clinical treatment
as well as for chemical modification on BBR.
Methods
Chemicals and reagents
Berberine (BBR) chloride (purity, 98%) was obtained
from Sigma Chemical Co. (St. Louis, MO, USA). Berber-
rubine (M1), thalifendine (M2) and demethyleneberber-
ine (M3) were synthesized by Chemical Department of
our institute. All of the study compounds were in purity
Figure 1 Chemical structure of berberine and its metabolites, berberrubine (M1), thalifendine (M2), demethyleneberberine (M3) and
jatrorrhizine (M4).
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chased from the National Institute for the Control of
Pharmaceutical and Biological Products (Beijing, China).
The CYP450 inhibitors a-naphthoflavone, quinidine and
ketoconazole were from J&K Chemical Ltd (Beijing,
China). HPLC-grade acetonitrile and methanol were
obtained from Fisher Scientific (New Jersey, USA).
Pooled mixture of liver microsomes (Gentest Lot No.
70196, USA) and a NADPH-regenerating system were
purchased from BD Gentest (Woburn, MA, USA).
Microsomes from cDNA-transfected baculovirus-insect
cells (expressing CYP1A2, CYP2A6, CYP2B6, CYP2C9,
CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5)
were also from the BD Gentest.
Animal experiments
Male Wistar rats (200-240 g, 8-week-old) purchased
from Vital River Laboratories (Beijing, China) fasted
overnight and were free access to water before drug
administration. Rats were treated with with BBR orally
(200 mg/kg weight, n = 8) or distilled water as negative
controls (n = 3), and rat livers were removed 3 hrs later.
2 g of the liver sample was washed with 5 mL normal
saline, cut into small pieces and extracted with 3-fold
volume acetonitrile. After vortexed for 3 min, the
extract was centrifuged at 16000 g for 15 min at 4°C
and the supernatant was diluted with 0.2% acetic acid.
Ten microlitre dilution aliquot was injected into the LC-
MS/MS system for analysis.
Structure-based BBR-CYP450 docking analysis
The crystal structures of the six CYP450 isoforms were
retrieved from the Protein Data Bank (PDB ID code
2HI4 for CYP1A2, solved at 1.95-Å resolution [12];
1Z11 for CYP2A6, 2.05-Å [13]; 1OG5 for CYP2C9,
2.55-Å [14]; 2F9Q for CYP2D6, 3.00-Å [15]; 3E4E for
CYP2E1, 2.60-Å [16]; 1TQN for CYP3A4, 2.05-Å
[17,18]). In this study, the docking was based on steric
considerations but orienting the substrate recognition
sites (SRSs) toward heme and ferryl oxygen of CYP450
protein [19,20]. A docking program FlexX (SYBYL 7.3,
Tripos Inc) that uses an incremental construction algo-
rithm was applied to optimize the interaction between
the ligands and the substrate binding sites [21]. As for
each of the CYP450 proteins, all crystal water molecules
were removed from the original structure, hydrogen was
added using Biopolymer module in SYBYL.
BBR metabolism in human liver microsomes (HLMs)
Incubation conditions were optimized to ensure the lin-
earity with respect to the microsomal protein concentra-
tion and incubation time [22-24]. A typical incubation
contained 0.1 mg of human liver microsomes, 100 mM
phosphate buffer (pH 7.4), BBR (dissolved in methanol,
final volume of methanol < 0.1% [25]) and NADPH-
regenerating system (at final concentration of 3.3 mM
glucose-6-phosphate, 1.3 mM NADP
+,0 . 4u n i t / m lg l u -
cose-6-phosphate dehydrogenase and 3.3 mM MgCl2)i n
a final volume of 200 μl. After pre-incubation of HLMs
with BBR for 5 min at 37°C, the reaction was initiated
by addition of NADPH-regenerating system. After incu-
bation of the mixture in a 37°C water bath with opening
to the air, the reaction lasted for 30 min and was termi-
nated by addition of 800 μl cold acetonitrile. Internal
standard (40 μg/ml ampicillin, dissolved in acetonitrile)
was added into the mixture, and then centrifuged at
16000 g for 15 min at 4°C. The supernatant was aspi-
rated, followed by dilution in 0.2% acetic acid. 10 μlo f
the aliquot was injected into the LC-MS/MS system for
analysis. Control samples were incubated without
NADPH. The incubation was performed in duplicates.
BBR metabolism in recombinant human CYP450
isoenzymes
The experiment was performed with the condition
described in the method using HLMs for transforma-
tion. 50 pmol/mL of each of the CYP450 isoenzymes
incubated with 20 μmol/L BBR. Control microsome pre-
pared from insect cells, which were infected with wild-
type baculovirus, severed as a negative control. The
incubation was performed in duplicates.
Chemical inhibition assays
a-Naphthoflavone [26] (typical inhibitor of CYP1A2;
final concentration used, 5 μM), quinidine [27,28] (typi-
cal inhibitor of CYP2D6; final concentration, 5 μM) sul-
faphenazole [23] (typical inhibitor of CYP2C9; final
concentration, 5 μM), troglitazone [23] (typical inhibitor
of CYP2C19; final concentration, 5 μM) and ketocona-
zole [29] (typical inhibitor of CYP3A; final concentra-
tion, 5 μM) were added, respectively, to the incubation
reaction containing 0.5 mg/ml HLMs, 100 mM phos-
phate buffer (pH 7.4) and NADPH-regenerating system
at a final volume of 200 μl. Before addition of BBR (15
μM), the samples were pre-incubated for 10 min at 37°C
and transferred onto ice for 45 min. The mixture was
incubated at 37°C for 30 min and then terminated with
cold acetonitrile [30]. Sample analysis was described
above. The incubations were performed in duplicates.
Kinetic experiments
To measure the enzyme kinetic parameters both in
HLMs and rCYP450s, we adjusted the standard incuba-
tion mixture containing BBR at a final concentration
between 0.15~75 μM. Incubation conditions were as
described above. Samples were analyzed by LC-MS/MS.
The kinetic parameters Vmax and Km were calculated
using EK1 v10.0 program (SPSS Inc., Chicago, IL, USA),
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clearance (Clint, Vmax/Km). The results were expressed
as mean ± sd from three independent experiemnts. The
percentage of total normalized rate (%TNR) was calcu-
lated to estimate the contribution of each CYP450 in
BBR transformation [22].
LC-MS/MS analysis
Sample analysis was performed using an LC-MS/MS
system (Thermo-Finnigan, San Jose, CA, USA), which
consisted of a Surveyor LC pump with an on-line degas-
ser, a Surveyor autosampler and a TSQ Quantum triple-
quadrupole mass spectrometer equipped with an ESI
probe. A Waters XTerra
® MS C18 (2.1 ×50 mm, 3.5
μm) column (Milford, MA, USA) was used for separa-
tion at 25°C. The mobile phase consisted of 0.2% acetic
acid in water (A) and 100% acetonitrile (B). The flow-
rate was 0.2 ml/min. In gradient elution, the proportion
of acetonitrile (B) was linearly increased from 10% to
100% in 18 min, held at 100% for 2 min and returned to
10% in 0.1 min. The column was allowed to equilibrate
for 10 min after each run. Only the data from 2 min to
15 min was acquired by MS. The MS was operated in
positive ESI mode. Nitrogen was used as both the sheath
and auxiliary gas at a pressure of 35 and 10 arbitrary
units, respectively. The spray voltage was set at 4.0 kV
and the capillary temperature was at 270°C. Full scan
and product ion mass spectra results of BBR as well as
M1-M4 were obtained (data are not shown). The most
abundant product ion of each chemical was chosen for
selected reaction monitoring (SRM). The SRM transi-
tions and collision energies are shown in Table 1. Data
were analyzed by Xcalibur 1.2 software.
Cell culture and drug treatment
The Human hepatoma cell line HepG2 was obtained
from the American Tissue Culture Collection (ATCC,
USA). HepG2 cells were grown in Eagle’s Minimum
Essential Medium (GIBCO) supplemented with 10%
fetal bovine serum (GIBCO), 1% non-essential amino
acids (GIBCO) and 1% antibiotics (100 units/ml of peni-
cillin and 100 μg/ml of streptomycin), and incubated at
37°C in a humidified atmosphere with 5% CO2.
For real time RT-PCR and double immune-staining
analysis, HepG2 cells were starved in Eagle’s MEM sup-
plemented with 0.5% FBS overnight and treated with
BBR or its metabolites (M1-M4) for 8 hrs, respectively.
For immunoblot assay, cells were starved in serum-free
medium overnight and treated with BBR or its metabo-
lites (M1-M4) for 24 hrs. The study compounds were
diluted in culture medium prior to use.
RNA isolation and real-time RT-PCR
Total cellular RNAs were isolated by the Ultraspec RNA
lysis solution (Biotecxs Laboratory, Houston, TX) by fol-
lowing the vender’s instruction. Total RNAs were rever-
sely transcribed into cDNAs using the Reverse
Transcription System (Promega, Madison, WI). Quanti-
tative real time PCR was performed with these cDNAs
as described previously [2], with b-Actin as an internal
control. Normalized InsR or LDLR mRNA expression
levels were plotted as fold of the untreated control. The
primers used were described previously [2,3].
Double immune-staining and flow cytometry analysis
HepG2 cells were treated with BBR (27 μM), simvastatin
(1 μM) or rosiglitazone (10 μM) for 8 hrs, respectively.
The cells were harvested, washed in PBS and incubated
for 1 hr at 37°C in the presence of both monoclonal
antibody to InsR (Labvision/NeoMarkers, Fremont, CA)
and rabbit polyclonal antibody against LDLR (Santa
Cruz Biotechnology, Santa Cruz, CA). The correspond-
ing isotype-matched, nonspecific mouse and rabbit IgGs
were used respectively as controls for nonspecific stain-
ing. After washing in PBS, cells were stained with a
fluorescein isothiocyanate (FITC)-conjugated goat anti-
mouse IgG (green color, Santa Cruz Biotechnology), as
well as a tetramethyl rhodamine isothiocyanate
(TRITC)-conjugated goat anti-rabbit IgG (red color,
Santa Cruz Biotechnology). The fluorescence intensities
were analyzed in a FACS (FACSort, Becton Dickinson).
Immunoblot
Sample cells were rinsed with phosphate-buffered saline
and lysed in SDS-PAGE loading buffer. Cell lysates were
subjected to 8% SDS-PAGE for protein separation, and
protein bands were transferred onto polyvinylidene
difluoride membranes (Millipore). The amount of pro-
tein and extent of phosphorylation were estimated using
the following primary rabbit antibodies, anti-phospho-
AMPK-a-Thr-172 antibody, anti-AMPK-a antibody as
well as anti-b-actin antibody (Cell signaling Technology,
USA). The secondary antibody was peroxidase-conju-
gated goat anti-rabbit antibody (Cell signaling Technol-
ogy, USA). After binding, the bands were revealed with
enhanced chemiluminescence using the ECL commercial
kit (Millipore).
Table 1 SRM transitions and collision energies used in
LC-MS/MS for the detection of BBR, M1, M2, M3 and M4
Chemical Molecular mass
(MW)
SRM transition
(m/z)
Collision energy
(eV)
BBR 335 336.0®319.8 28
M1 321 322.0®306.8 31
M2 321 322.0®306.8 31
M3 323 324.0®307.8 32
M4 338 338.0®321.9 30
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Differences of mean results among study groups were
examined by a two-tailed unpaired Student’s t-test for
equal or unequal variances depending on a preliminary
F test for homogeneity of variance. Results are expressed
as the means ± sd. P < 0.05 was considered significant.
Results and Discussion
BBR metabolites are detectable in rat’s liver tissue
It has been documented that BBR has four major meta-
bolites after phase I metabolism in vivo,b e r b e r r u b i n e
(M1), thalifendine (M2), demethyleneberberine (M3) and
jatrorrhizine (M4) [31]. The chemical structures of the
four compounds are shown in Figure 1. These metabo-
lites were detectable in the blood and urine in human
and rodents [11,31]. The biotransformation of BBR in
rats was reported to be similar to that in human [31]. As
BBR’s activity was examined in hepatocytes in our pre-
vious experiments [2-4], we detected the BBR metabolites
in rat liver to address the question of whether hepato-
cytes contain these metabolized products. In the present
study, the 4 metabolites M1, M2, M3 and M4 were all
detectable in rat livers 3 hrs after BBR oral administration
(Figure 2). The highest level was seen in M2 and the low-
est in M1. The result was consistent with the previous
reports of BBR metabolites in rodent blood [11,31].
CYP450 isoenzymes that involved in BBR phase I
metabolism
For BBR’s metabolite formation in liver, our question
was which of the CYP450 isoenzymes transform BBR
into its metabolites. Thus, nine major recombinant
human CYP450 isoenzymes (CYP1A2, CYP2A6,
CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1,
CYP3A4 and CYP3A5) were investigated in this study.
Of the nine isoenzymes, six (CYP1A2, CYP2A6,
CYP2C9, CYP2D6, CYP2E1 and CYP3A4) have their 3-
D structural database available from PDB (Protein Data
Bank). As the initial step, computer-assistant docking
analysis was performed using SYBYL 7.3 system for the
affinity between BBR and each isoenzyme. As shown in
Figure 3a for the docking score, the CYP2D6, CYP1A2
and CYP3A4 exhibited considerably good docking per-
formance with respect to the positive docking cut-off
value set at 5. The molecular interactions between BBR
and the three CYP450s are shown in Figure 3b. BBR
anchored in the binding site of CYP2D6 through hydro-
gen bond interaction with the side chain of Arg-221;
Phe-120 played a major role in controlling the orienta-
tion of BBR to the heme; the Phe-483 made a cross lock
to the C- and D-ring of BBR (Figure 3b, upper). The
substrate binding cavity of CYP1A2 was uniformly nar-
row throughout its extent and was lined by residues
Gly-316-Ala-317 and the Asp-320 peptide bond, which
constituted a relatively planar substrate binding plat-
form. Phe-226 produced another parallel substrate bind-
ing surface and a π-π stacking with BBR. In addition,
both orthogonal and parallel aromatic interactions
between BBR and residues Phe-125 and Phe-226 con-
tributed to a tight binding affinity. Also, a water mole-
cule of CYP1A2 hydrogen-bonding to BBR and Gly-316
strengthens this binding (Figure 3b, middle). In the
BBR-CYP3A4 docking pattern, hydrogen bonding and
orthogonal aromatic interactions were observed between
Figure 2 BBR and its main phase-I metabolites in rat liver. Male Wistar rats (200-240 g, 8-week-old) were orally treated with BBR (200 mg/
kg). Rat livers (n = 8) were removed 3 hrs later, followed by homogenization, cell lysate extraction and LC MS/MS detection. Presented are
mean and sd of the 8 rats. Untreated control rats (n = 8) were used for comparison.
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Figure 3 Identification of CYP450 isoenzymes that transform BBR into its metabolites. Interaction between CYP450 and BBR were
analyzed with docking score generated from SYBYL 7.3 software analysis. CYP450 isoenzymes with docking scores over 5 were labelled with the
score value (a). The 3-D structrual docking patterns between BBR and CYP2D6 (upper), or CYP1A2 (middle), or CYP3A4 (lower) were generated
with SYBYL 7.3. BBR is rendered in sticks (red, oxygen atoms; white, carbon atoms; blue, nitrogen atoms). The heme prosthetic group is rendered
in sticks in red. The amino acid residues constituting the active site cavity are in cyan, most of which are shown in lines. Amino acid residues
rendered in sticks may help BBR binding to CYP450. Specific hydrogen bonds and a water molecule are showed as yellow broken lines and a
red sphere, respectively (b). For the transformation test in rCYP450 isoenzymes reaction system, BBR (20 μM) was incubated with each of the
rCYP450 isoenzymes (50 pmol/ml of rCYP450) for 0.5 hr, followed by a detection of the metabolites. The experiment was repeated twice (c). In
the chemical inhibition assay, the a-naphthoflavone (ANF) was for CYP1A2 inhibition, quinidine (QND) for CYP2D6, ketoconazole (KET) for CYP3A,
sulfaphenazole (SUP) for CYP2C9 and troglitazone (TGL) for CYP2C19. BBR was incubated with HLMs in the presence or absence of CYP450
specific inhibitors. The final concentration of BBR and the inhibitor in the reaction was 15 μM and 5 μM, respectively. The enzyme catalyzing
activity of sample free of inhibitors (control) was defined as 100%. Presented is mean and sd of the percent of control (d).
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(Figure 3b, lower) .T h er e s u l t ss u g g e s tt h a tt h et h r e e
cellular CYP450 isoenzymes might have good binding
affinity to BBR.
Then, the docking experiment was corroborated with
biochemical assay. Each of the above-mentioned
CYP450 isoenzymes was in turn incubated with BBR for
30 min, followed by detection of BBR metabolites with
LC-MS/MS. The results are shown in Figure 3c. Treat-
ment of BBR with CYP2D6 and CYP1A2 generated a
considerable level of M2 and M3, suggesting that they
were the dominant contributors to transform BBR into
M2 and M3. CYP3A4 was also important for the pro-
duction of M3 but only with a minor role in M2 pro-
duction. In addition, CYP2C19, CYP2C9 and CYP3A5
showed some very weak effect in producing M2 and
M3, respectively. CYP2A6, CYP2B6 and CYP2E1 were
without effect on BBR transformation. Although the
experiment was repeated for over 5 times, M1 and M4
were not detectable in the reaction system.
If the results were true, inhibition of the CYP450 iso-
enzymes should reduce the formation of the metabolites.
Therefore, chemical inhibition assays were carried out in
the HLMs reaction system for the CYP2D6-, CYP1A2-,
CYP3A-, CYP2C9-, or CYP2C19-mediated BBR trans-
formation, respectively. BBR was treated with HLMs for
30 min in the presence or absence of specific CYP450
isoenzyme inhibitors. The effects of the inhibitors on
BBR metabolism in HLMs reaction were shown in Fig-
ure 3d. The reaction activity of the control sample (with
no inhibitor) was defined as 100% for the comparison
with that of the samples treated with inhibitors. M2 for-
mation was decreased by about 40% after ANF (for
CYP1A2) or QND (for CYP2D6) treatment, but not
KET treatment (for CYP3A); M3 formation decreased
by around 20% after treatment with inhibitor for
CYP1A2, or CYP2D6, or CYP3A; inhibitors for CYP2C9
and CYP2C19 showed only minor or no effect. Accord-
ingly, BBR disappearance was found decreased in the
reactions treated with inhibitors for CYP1A2, CYP2D6
and CYP3A, but not with those for CYP2C9 and
CYP2C19. The sum of reduction in the formation of
M2 and M3 were close to the reduction of berberine
disappearance (Figure 3d). The results showed the role
of the three CYP450 isoenzymes in the BBR phase-I
metabolism, and were consistent with that from compu-
ter docking. The inhibition rate of each of the inhibitors
for CYP1A2, CYP2D6 and CYP3A was in the range
between 15-40%. The inhibitory efficacy of each of the
inhibitors was not strong (especially for the inhibition of
M3 formation), indicating a combined effect of the three
major isoenzymes in BBR’s transformation.
Considering the relative expression of these CYP450
isoforms in liver, enzyme kinetic study using these
CYP450 isoenzymes was performed and the relative
contribution of each of the CYP450 isoenzymes was cal-
culated. The results were in Table 2 and 3. For M2 pro-
duction, the contribution rate of CYP1A2, CYP2D6 and
CYP3A4 was 72.07%, 25.21% and 2.72%, respectively.
For M3, the contribution rate was 26.36%, 37% and
36.63% for CYP1A2, CYP2D6 and CYP3A4, respectively.
Activity of the BBR metabolites on InsR, LDLR and AMPK
Next, each of the BBR metabolite compounds was
examined for their effect on the expression of InsR and
LDLR mRNA, as well as on the activity of AMPK in
human hepatocytes. For LDLR mRNA expression, the
original BBR remained to be the strongest up-regulator
(Figure 4a); among the 4 metabolites, M1 and M2
remained to be active with an activity 35% and 26% of
that of BBR, respectively; M3 and M4 were without
effect. Although the 4 metabolites were active in
increasing InsR mRNA level in HepG2 hepatocytes by
around 1.5 folds, the original form of BBR appeared to
be the most active one up-regulating InsR mRNA level
by over 2 folds (Figure 4b). It suggests that BBR in its
original form is the most potent functional compound
for the hypoglycemic as well as lipid-lowering effect in
clinic. To compare BBR’s effect with the known type 2
diabetes drug rosiglitazone and anti-cholesterol drug
simvastatin, double immune-staining was conducted for
the cell-surface protein expression of InsR and LDLR.
The results demonstrated an up-regulatory effect of BBR
on both LDLR and InsR on the membrane of human
hepatocytes, suggesting a unique effect of BBR on the
two major molecules related to energy metabolism. In
contrast, simvastatin increased LDLR expression only,
but not InsR; and rosiglitazone showed effect on neither
LDLR nor InsR (Figure 4c). The results hint an advan-
tage of BBR over the known drugs in modulating cellu-
lar energy metabolism.
AMPK’s activity closely associates with sugar metabo-
lism. Kim et al has reported that BBR reduced blood
glucose through activation of AMPK in adipose cells [9].
Here, we tested BBR metabolites for their activity on
this kinase in liver cells. As shown in Figure 4d, among
Table 2 CYP450s responsible for M2 formation
CYP1A2 CYP2D6 CYP3A4
Km (μM) 100.0 ±
8.74
31.9 ±
1.23
27.8 ± 0.79
Vmax (pmol/min/pmol P450) 5.4 ±
0.094
2.7 ±
0.0052
0.024 ±
0.0021
Clint (μL/min/pmol P450) 0.054 0.085 0.00085
Nominal P450 Content in HLMs
(pmol/mg)
45 10 108
Adjusted Clint (μL/min/mg) 2.43 0.85 0.0918
Percentage Adjusted Clint (%) 72.07 25.21 2.72
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compound for AMPK activation; the treatment of
HepG2 human liver cells with M1 and M2 increased the
activity of AMPK but with a less potency as compared
to that of BBR; the effect of M3 and M4 on this kinase
appeared to be not significant. The experiment was
repeated for more than 3 times and the results were
reproducible. As the BBR bioactivities were kept at cer-
tain degrees in the metabolites with an intact E ring
(M1 and M2), but abolished in those with E ring opened
Table 3 CYP450s responsible for M3 formation
CYP1A2 CYP2D6 CYP3A4
Km (μM) 125.8 ±
3.57
12.0 ±
0.68
27.1 ±
1.03
Vmax (pmol/min/pmol P450) 4.8 ± 0.54 2.9 ±
0.19
0.59 ±
0.012
Clint (μL/min/pmol P450) 0.038 0.24 0.022
Nominal P450 Content in HLMs
(pmol/mg)
45 10 108
Adjusted Clint (μL/min/mg) 1.71 2.4 2.376
Percentage Adjusted Clint (%) 26.36 37.0 36.63
Figure 4 Effect of BBR metabolites on InsR, LDLR and AMPK. HepG2 cells were respectively treated with the compounds for 8 hrs at
concentration of 20 μM for InsR test or 40 μM for LDLR, followed by RNA extraction and real time RT-PCR assay for the InsR or LDLR mRNA. The
amount of LDLR (a) and InsR (b) mRNA in the treated cells was normalized to that of the untreated control. * p < 0.05, **p < 0.01, vs the
untreated control. To detect the protein expression, HepG2 cells were treated with BBR (27 μM) for 8 hrs, with simvastatin (1 μM) and
rosiglitazone(10 μM) as references. Berberine increased the cell-surface expression of both InsR and LDLR in the hepatocytes (c). For AMPK
activation, HepG2 cells were treated with the study compounds (20 μM) for 24 hrs with DMSO as a control. AMPK-alpha phosphorylation in the
HepG2 cells was detected with immunoblots, using a protocol described in the Methods (d).
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Page 8 of 10(M3 and M4), the presence of E ring on BBR (Figure 1)
seems to be essential for their activity on LDLR and
AMPK, consistent with our previous observation [32].
The analysis of the functional group of BBR has led us
t oac r e a t i o no fa nM 1p r o - d r u g ,w h i c hd e m o n s t r a t e d
an increased efficacy as compared with BBR [33].
BBR is a safe medicine with multiple therapeutic
effects. This compound has a poor absorption rate in
human gut with less than 10% of BBR entering into
blood stream [34]. BBR were metabolized into at least
four metabolites after phase-I metabolism in vivo.T h i s
study shows for the first time that CYP1A2, CYP2D6
and CYP3A4 are the major contributors for the trans-
formation of BBR into its metabolites in human liver
microsomes. The main metabolites detectable in the
enzymatic reaction were M2 and M3; M1 and M4 were
not found after incubation of BBR with recombinant
CYP450s or the HLMs mixture. As the sensitivity of our
LC-MS/MS test was in 100~500 pg range, the M1 and
M4 content might be under this level in the reactions.
Further optimization of the experimental condition
might help us to identify these two metabolites although
their concentration seemed to be extremely low in these
reactions. It is worthy to note that statins are mainly
metabolized under the action of CYP3A4 [35,36], rela-
tively different from that in BBR. The information might
be helpful in designing clinical therapeutic regimen
combining statins with BBR [7].
Also, this study shows for the first time that although
BBR itself is the most active compound to up-regulate
InsR expression, all of its metabolites remain to be active
at certain degree on this target. For LDLR up-regulation
and AMPK activation, M1 and M2 are the two active
metabolites, with reduced potency. The study suggests
that the action of BBR on cellular energy metabolism
pathways mainly originates from BBR in its original form.
Conclusions
Taken together, four major BBR metabolites (M1-M4)
were identified after phase-I transformation in rat liver.
CYP1A2, CYP2D6 and CYP3A4 appeared to be the key
enzymes to transform BBR into M2 and M3 in cell-free
metabolism reactions. The metabolites of BBR remained
to be active on InsR (by M1-4), LDLR (by M1 and M2),
and AMPK (by M1 and M2), but with largely reduced
potency. It appears that BBR in its original form is the
active chemical entity that regulates multiple pathways
in energy metabolism.
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